Other · developed by Hutchmed
HMPL-A251 is an agent given by intravenous infusion, studied in adult patients with solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07228247 | Phase 1/2 | Solid Tumors, Adult | Recruiting | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumors, Adult
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →